Eikon Therapeutics, Inc. - Common Stock (EIKN)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Aug 22, 2026Investment Snapshot
- P/B of 1.46 — trading near book value
- Piotroski F-Score 0/9 — signs of financial weakness
- Loss-making — negative ROE of -73.9%
Eikon Therapeutics, Inc. - Common Stock (EIKN) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $679 million . Key value metrics: P/B ratio 1.46, Piotroski F-Score 0 out of 9 .
Value Score
Key Metrics
Eikon Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, EIKN shows a weak Piotroski F-Score of 0/9, a signal of deteriorating financial health, and negative return on equity of -73.9% (sector average: -20.1%).
StockPik's composite Value Score for EIKN is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.